Navigation Links
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Date:5/22/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...enter and Children's Medical Center Dallas say tha... muscle fibers// that are affected by cancer. The ...cer develops. It could also offer clues in search ...animal model system shown that new cells can be ge...
...c people and the possible link between these chang...the Wake Forest University School of Medicine// . ...e diagnosed with schizophrenia or bipolar disorder... be done by the team under a 5-year $1.1 million ...
...y that the media is insensitive to the disease and... "I have come across journalists refusing to sha...t even look at my eyes during interview sessions. ...p in breaking the stigma," said Vanlalmuana, the p...
...ht social stigma, HIV carriers in Jharkhand have f...r People Living with HIV has 200 members. More are...le to treat HIV carriers in a humane manner. It wi...nment to ensure adequate healthcare facilities and...
Other Medicine News:Health News:Cancer Affects Mature Muscle Fibers 2Health News:Brain changes in schizophrenia to be analyzed 2Health News:Brain changes in schizophrenia to be analyzed 3
(Date:9/3/2008)...and GENEVA, Sept. 3 /- Artelis SA and... based monoclonal antibody,production with the ach...per liter. This record level was accomplished by a...high-performance stable Selexis CHO,production cel...tists at,Selexis SA using their proprietary Selexi...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008)... /-, - This Analysis Showe...of Stroke by 34% in Patients With Atrial Fibrillat...y Antithrombotic Therapy, The results of a post-h... presented today at the clinical trial update sess... 2008, in Munich, Germany. Previous results,from t...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Biotage Launches New 24 Well Pyrosequencing 28R 29 System 4286 1Biotage Launches New 24 Well Pyrosequencing 28R 29 System 4286 2Turn that frown upside down healthy gums are something to smile about 15548 1Turn that frown upside down healthy gums are something to smile about 15548 2Scientists 3A New technique identifies molecular biomarkers for disease 15546 1Scientists 3A New technique identifies molecular biomarkers for disease 15546 2Scientists 3A New technique identifies molecular biomarkers for disease 15546 3Ohio Faith Leaders Call on Sen Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 15544 1Ohio Faith Leaders Call on Sen Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 15544 2
...ous administration show potential for,new option t...e 04, 2007 /PRNewswire-FirstCall/ -- Millennium,Ph...on of positive,data for VELCADE, the market-leadin...who have received at least one prior therapy.,Thes...ubcutaneous,(SC) administration of VELCADE, a new ...
... With Follicular Lymphoma Reported,Today at ASCO A...wire/ -- GlaxoSmithKline plc,announced today long-...le one-week course of frontline treatment with the...dine I-131 Tositumomab) in,76 patients with newly ...ma (NHL). This regimen was found to induce durable...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
Full Handle Laseredge Implant Blade Knife, 6.0 pilot tip. Blade dimension: 16.5 mm x 6.0 mm x 4.2 mm x 2.4 mm.
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip. Blade dimension: 14.4 mm x 3.2 mm x 3.8 mm x 1.65 mm.
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm.
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm.
Medicine Products: